[HTML][HTML] Reactive astrocytes in neurodegenerative diseases

K Li, J Li, J Zheng, S Qin - Aging and disease, 2019 - ncbi.nlm.nih.gov
Astrocytes, the largest and most numerous glial cells in the central nervous system (CNS),
play a variety of important roles in regulating homeostasis, increasing synaptic plasticity and …

Pyroptosis in health and disease: mechanisms, regulation and clinical perspective

Y Liu, R Pan, Y Ouyang, W Gu, T Xiao… - Signal transduction and …, 2024 - nature.com
Pyroptosis is a type of programmed cell death characterized by cell swelling and osmotic
lysis, resulting in cytomembrane rupture and release of immunostimulatory components …

Astrocytic modulation of blood brain barrier: perspectives on Parkinson's disease

R Cabezas, M Ávila, J Gonzalez… - Frontiers in cellular …, 2014 - frontiersin.org
The blood–brain barrier (BBB) is a tightly regulated interface in the Central Nervous System
(CNS) that regulates the exchange of molecules in and out from the brain thus maintaining …

Artificial intelligence techniques for automated diagnosis of neurological disorders

U Raghavendra, UR Acharya, H Adeli - European neurology, 2020 - karger.com
Background: Authors have been advocating the research ideology that a computer-aided
diagnosis (CAD) system trained using lots of patient data and physiological signals and …

Safety and tolerability of gene therapy with an adeno-associated virus (AAV) borne GAD gene for Parkinson's disease: an open label, phase I trial

MG Kaplitt, A Feigin, C Tang, HL Fitzsimons, P Mattis… - The Lancet, 2007 - thelancet.com
Background Dopaminergic neuronal loss in Parkinson's disease leads to changes in the
circuitry of the basal ganglia, such as decreased inhibitory GABAergic input to the …

Mechanisms of disease: astrocytes in neurodegenerative disease

NJ Maragakis, JD Rothstein - Nature clinical practice Neurology, 2006 - nature.com
The term neurodegenerative disease refers to the principal pathology associated with
disorders such as amyotrophic lateral sclerosis, Alzheimer's disease, Huntington's disease …

Diagnosis and treatment of Parkinson disease: molecules to medicine

JM Savitt, VL Dawson… - The Journal of clinical …, 2006 - Am Soc Clin Investig
Parkinson disease (PD) is a relatively common disorder of the nervous system that afflicts
patients later in life with tremor, slowness of movement, gait instability, and rigidity …

Drug discovery in the ubiquitin–proteasome system

G Nalepa, M Rolfe, JW Harper - Nature reviews Drug discovery, 2006 - nature.com
Regulated protein turnover via the ubiquitin–proteasome system (UPS) underlies a wide
variety of signalling pathways, from cell-cycle control and transcription to development …

Levodopa in the treatment of Parkinson's disease: an old drug still going strong

W Poewe, A Antonini, JCM Zijlmans… - … interventions in aging, 2010 - Taylor & Francis
After more than 40 years of clinical use, levodopa (LD) remains the gold standard of
symptomatic efficacy in the drug treatment of Parkinson's disease (PD). Compared with other …

Place of cabergoline in acromegaly: a meta-analysis

L Sandret, P Maison, P Chanson - The Journal of Clinical …, 2011 - academic.oup.com
Context: Cabergoline is widely considered to be poorly effective in acromegaly. Objective:
The aim of this study was to obtain a more accurate picture of the efficacy of cabergoline in …